6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes
Public ClinicalTrials.gov record NCT00993473. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24-week, Randomized, Open-label, Parallel Group Multinational Comparison of Lantus® (Insulin Glargine) Given in the Morning as Once-a-day Basal Insulin Versus Neutral Protamine Hagedorn (NPH) Insulin, in Children With Type 1 Diabetes Mellitus Aged at Least 1 Year to Less Than 6 Years
Study identification
- NCT ID
- NCT00993473
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Sanofi
- Industry
- Enrollment
- 125 participants
Conditions and interventions
Conditions
Interventions
- Insulin glargine (HOE901) Drug
- Insulin lispro Drug
- Neutral Protamine Hagedorn (NPH) insulin Drug
Drug
Eligibility (public fields only)
- Age range
- 1 Year to 6 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2009
- Primary completion
- Feb 28, 2011
- Completion
- Feb 28, 2011
- Last update posted
- Jun 26, 2012
2009 – 2011
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sanofi-Aventis Investigational Site Number 840006 | Sacramento | California | 95819 | — |
| Sanofi-Aventis Investigational Site Number 840014 | San Diego | California | 92123 | — |
| Sanofi-Aventis Investigational Site Number 840005 | Greenwood Village | Colorado | 80111 | — |
| Sanofi-Aventis Investigational Site Number 840008 | Baltimore | Maryland | 21229 | — |
| Sanofi-Aventis Investigational Site Number 840007 | Buffalo | New York | 14222 | — |
| Sanofi-Aventis Investigational Site Number 840011 | Philadelphia | Pennsylvania | 19104 | — |
| Sanofi-Aventis Investigational Site Number 840010 | Houston | Texas | 77030 | — |
| Sanofi-Aventis Investigational Site Number 840002 | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00993473, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 26, 2012 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00993473 live on ClinicalTrials.gov.